Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction.

@article{Kendirci2004VardenafilAN,
  title={Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction.},
  author={Muammer Kendirci and Trinity J. Bivalacqua and Wayne J G Hellstrom},
  journal={Expert opinion on pharmacotherapy},
  year={2004},
  volume={5 4},
  pages={923-32}
}
Orally administered phosphodiesterase type 5 (PDE5) inhibitors have become the first-line treatment option for erectile dysfunction (ED). Vardenafil is a potent and highly selective PDE5 inhibitor developed as an oral therapy for ED. Two pivotal, randomised, double-blind, multi-centre studies have evaluated the use of vardenafil in men with ED. Vardenafil… CONTINUE READING